Page last updated: 2024-10-24

positive regulation of establishment of endothelial barrier

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of establishment of endothelial barrier. [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24851274]

Positive regulation of establishment of endothelial barrier is a complex process that ensures the integrity and functionality of the endothelial lining of blood vessels. This process involves the coordinated action of various cellular signaling pathways, adhesion molecules, and cytoskeletal components. Here is a detailed description:

1. **Signal transduction pathways:**
* **VEGF signaling:** Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and vascular permeability. VEGF binds to its receptors (VEGFR1 and VEGFR2) on endothelial cells, triggering downstream signaling cascades. These pathways activate various transcription factors, including NF-κB and STAT3, which regulate the expression of genes involved in endothelial barrier formation.
* **TGF-β signaling:** Transforming growth factor-beta (TGF-β) is a potent regulator of endothelial barrier function. Binding of TGF-β to its receptors activates SMAD signaling, leading to the expression of genes that promote cell-cell adhesion and tight junction formation.
* **Other pathways:** Other signaling pathways, such as those involving Wnt, Notch, and MAPK, also contribute to the regulation of endothelial barrier function.
2. **Adhesion molecules:**
* **Tight junctions:** Tight junctions are specialized cell-cell junctions that seal the spaces between endothelial cells, preventing the leakage of fluids and solutes. Tight junction proteins, including claudins, occludin, and junctional adhesion molecules (JAMs), are crucial for maintaining endothelial barrier integrity.
* **Adherens junctions:** Adherens junctions provide strong cell-cell adhesion through the interaction of cadherin family proteins. These junctions contribute to the overall stability and organization of the endothelial barrier.
3. **Cytoskeletal components:**
* **Actin filaments:** Actin filaments form a network beneath the cell membrane, providing structural support and regulating cell shape. Changes in actin dynamics, including polymerization and depolymerization, are essential for endothelial barrier formation and remodeling.
* **Microtubules:** Microtubules are long, hollow cylinders that facilitate intracellular transport and contribute to cell polarity. Microtubule dynamics play a role in the trafficking of junctional proteins and other components required for barrier formation.
4. **Extracellular matrix interactions:**
* **Basement membrane:** The basement membrane, a specialized extracellular matrix, provides structural support to the endothelium and regulates cell behavior. Interactions between endothelial cells and components of the basement membrane, such as laminin and collagen, are crucial for barrier formation and maintenance.

The precise mechanisms of positive regulation of endothelial barrier establishment are complex and vary depending on the specific context. However, the coordinated action of these signaling pathways, adhesion molecules, and cytoskeletal components ensures the formation of a robust and functional endothelial barrier, crucial for maintaining vascular integrity and regulating vascular permeability.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Vitamin K-dependent protein CA vitamin K-dependent protein C that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04070]Homo sapiens (human)
Sphingosine 1-phosphate receptor 2A sphingosine 1-phosphate receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:O95136]Homo sapiens (human)

Compounds (26)

CompoundDefinitionClassesRoles
5-(n,n-hexamethylene)amiloride5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.

5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity
aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines
antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker
amilorideamiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.

Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
aromatic amine;
guanidines;
organochlorine compound;
pyrazines
diuretic;
sodium channel blocker
fingolimodfingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.aminodiol;
primary amino compound
antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
cyc 202seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.2,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
melagatranazetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound
anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
razaxabanrazaxaban: structure in first source
dabigatrandabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.

Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines
anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor
1-[2-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-oxoethyl]pyrrolidine-2,5-dionearomatic ketone
(3-hydroxyphenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethionearomatic amine
1-[4-(3-ethoxyphenoxy)butyl]imidazolearomatic ether
bms 387032N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source

N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.
1,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sew2871SEW2871: structure in first sourceoxadiazole;
ring assembly
5-[[(2-methylanilino)-sulfanylidenemethyl]amino]-1H-pyrazole-4-carboxylic acid methyl esterthioureas
sphingosine 1-phosphatesphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1

sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
alvocidibalvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.

alvocidib: structure given in first source
dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamidearomatic amide;
heteroarene
bms 7408081-(3-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-6-(2'-(3-hydroxy-N-pyrrolidinyl)methyl-(1,1')-biphen-4-yl)-1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-one: structure in first source
dpc 423
fty 720pfingolimod phosphate : A primary amino compound that is fingolimod in which one on the hydroxy groups has been converted into its dihydrogen phosphate derivative. It is the active metabolite of fingolimod.monoalkyl phosphate;
primary alcohol;
primary amino compound
antineoplastic agent;
immunosuppressive agent;
sphingosine-1-phosphate receptor agonist
gw 813893
jte 013JTE 013: an Edg-5 antagonist

JTE-013 : A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM).
chloropyridine;
pyrazolopyridine
anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist
betrixabanbetrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.

betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source
benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide
anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
rpr 120844
fty 720p
cym-5442oxadiazole;
ring assembly
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source